Skandinaviska Enskilda Banken AB publ Raises Stock Position in Solventum Co. (NYSE:SOLV)

Skandinaviska Enskilda Banken AB publ lifted its position in Solventum Co. (NYSE:SOLV) by 51.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 82,767 shares of the company’s stock after buying an additional 28,154 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Solventum were worth $5,467,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Trian Fund Management L.P. boosted its stake in Solventum by 32.9% in the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock worth $496,842,000 after purchasing an additional 1,765,676 shares in the last quarter. State Street Corp lifted its stake in Solventum by 3.1% during the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after acquiring an additional 185,938 shares during the period. Geode Capital Management LLC lifted its stake in Solventum by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock valued at $232,608,000 after acquiring an additional 128,317 shares during the period. Hotchkis & Wiley Capital Management LLC acquired a new stake in Solventum during the 3rd quarter valued at approximately $125,488,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Solventum by 0.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,053,771 shares of the company’s stock valued at $73,469,000 after acquiring an additional 3,745 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts have commented on SOLV shares. Piper Sandler lifted their price objective on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research note on Friday, February 28th. Bank of America lifted their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, February 26th. The Goldman Sachs Group lifted their price objective on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. Mizuho lifted their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Finally, Morgan Stanley lifted their target price on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $79.86.

Solventum Price Performance

Shares of NYSE SOLV opened at $74.31 on Friday. The firm has a market cap of $12.85 billion and a PE ratio of 27.02. The firm has a fifty day moving average of $74.52 and a 200 day moving average of $71.14. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum Co. has a one year low of $47.16 and a one year high of $85.92.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.